Emcure Pharmaceuticals informs about outcome of board meeting

07 Aug 2025 Evaluate
In continuation to letter dated July 28, 2025, and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), Emcure Pharmaceuticals has informed that the Board of Directors of the Company at its meeting held today i.e. Thursday, August 07, 2025, has approved the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2025, as reviewed and recommended by the Audit Committee. Pursuant to Regulation 33 of the SEBI Listing Regulations, it enclosed the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2025, along with the Limited Review Reports on the aforesaid Results as issued by BSR & Co. LLP, Chartered Accountants, Auditors of the Company, enclosed as Annexure A. Press Release outlining key updates on the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2025, is also enclosed as Annexure B. The meeting of the Board of Directors of the Company commenced at 11.45 am (IST) and concluded at 1.20 pm (IST). 

The above information is a part of company’s filings submitted to BSE.

Emcure Pharma Share Price

1395.15 -9.10 (-0.65%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×